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Abstract 
Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc 
Therapy (VMAT) have become effective tools for treating cancer with radiation. 
Designing a high quality IMRT/VMAT treatment plan is time consuming. Different 
knowledge-based methods are being developed to reduce planning time and improve 
plan quality by extracting parameters from prior expert plans to form knowledge 
models and applying such models to the new patient cases. Currently, these methods 
mostly generate models for one particular cancer type and therefore various disease 
types require training of multiple knowledge models with a large number of cases.  
To investigate the feasibility of IMAT/VMAT treatment planning knowledge 
modeling for multiple cancer types, a progressive study was designed to build a 
treatment planning knowledge model that quantifies correlations between patient pelvic 
anatomical features and the Organ-At-Risk (OAR) sparing features from different 
disease types. Low-risk prostate plans with relatively simple Planning Target Volume  
(PTV) to OAR geometry, which has been the most common geometry type studied in 
previous knowledge based studies, were used to train the model as the starting point of 
the progressive modeling process. Cases with more complex PTV-OAR anatomies 
(prostate cancer cases with lymph node irradiation and anal rectal cancer cases) were 
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added to the training dataset sequentially until the model prediction accuracies reached 
plateau. The Dose Volume Histograms (DVHs) predicted by the knowledge model for 
the bladder, the femoral heads and the rectum were validated by clinical plans from all 
three types of cases. Dosimetric parameters extracted from the predicted DVHs and the 
corresponding actual plan values were compared for prediction accuracy of this multi-
disease type knowledge model. Further, the prediction accuracy was also compared 
with the models trained with three single disease type cases (including low-risk prostate 
cancer (type 1), high-risk prostate cancer with lymph nodes (type 2) and anal rectal 
cancer (type 3), respectively).  
Prediction accuracy reached a plateau when six high-risk prostate cancer cases 
and eight anal rectal cancer cases were added to the training dataset. The determination 
coefficients R2 for the OARs are: bladder: 0.90, rectum: 0.64 and femoral heads: 0.82. 
There is no significant difference in prediction accuracy between the multi-disease type 
model and the single-disease type models (F-test p-value: bladder: 0.58, rectum: 0.97 and 
femoral heads: 0.44).  
 
 
 
  
vi
Contents 
Abstract ......................................................................................................................................... iv 
List of Tables .............................................................................................................................. viii 
List of Figures ............................................................................................................................... ix 
Acknowledgements ..................................................................................................................... xi 
List of Abbreviations .................................................................................................................. xii 
1. Introduction ............................................................................................................................... 1 
2. Methods and Materials............................................................................................................. 6 
2.1 Mathematical phantoms .................................................................................................. 6 
2.2 Patient cases ...................................................................................................................... 7 
2.2.1 Prostate IMRT plans .................................................................................................... 8 
2.2.1.1 Low-intermediate risk prostate plans (type 1) ................................................. 8 
2.2.1.2 High-risk prostate plans with lymph node irradiation (type 2) .................... 9 
2.2.1.3 OAR constraints for prostate cancer IMRT/VMAT planning ...................... 10 
2.2.2 Anal rectal cancer IMRT plans (type 3) .................................................................. 12 
2.3 Knowledge-based OAR sparing models ..................................................................... 14 
2.3.1 Anatomical and dosimetrical features for knowledge modeling ....................... 14 
2.3.2 Principal component analysis for the DTHs and DVHs ...................................... 17 
2.3.3 Correlation between patient anatomical features and OAR DVH sparing 
features ................................................................................................................................. 19 
2.4 Building a knowledge model for multiple disease type ........................................... 20 
   2.4.1 Variation of anatomical features of each type cases ............................................ 20 
  
vii
   2.4.2 The process of progressive modeling .................................................................... 21 
   2.4.3 Dosimetric parameters for evaluating the models............................................... 22 
2.5 Accuracy evaluation of multi-disease type model .................................................... 23 
3. Results ....................................................................................................................................... 25 
3.1 The analysis of the results from mathematical phantom .......................................... 25 
3.2 Progressive modeling .................................................................................................... 28 
   3.2.1 Variations of different anatomical features scores ............................................... 28 
   3.2.2 Results for prostate with lymph nodes cases (type 2) ......................................... 31 
   3.2.3 Results for anal rectal cases (type 3) ...................................................................... 33 
3.3 Evaluation of the knowledge models in pelvic region .............................................. 34 
   3.3.1 Significant anatomical features of the models ...................................................... 34 
   3.3.2 Correlation of actual DVH PCS and fitted DVH PCS ......................................... 37 
   3.3.3 Statistic tests of the single/multiple-disease type models ................................... 39 
   3.3.4 DVHs of validation cases ........................................................................................ 41 
4. Discussion ................................................................................................................................ 45 
5. Conclusion ............................................................................................................................... 47 
References .................................................................................................................................... 48 
 
  
viii
List of Tables 
Table 1: Dose prescriptions and PTVs in different types of prostate cancer ...................... 11 
Table 2: Normal tissue constraints for prostate IMRT used in Duke University Cancer 
Center ............................................................................................................................................ 12 
Table 3: Dose prescriptions and PTVs in an example of the   customized anal rectal case
 ....................................................................................................................................................... 13 
Table 4: Normal tissue constraints for an example of the customized anal rectal case .... 14 
Table 5: The OARs and their anatomical features analyzed in this study .......................... 17 
Table 6: Significant anatomical features contributing to the OAR DVH PCS1 (single-
disease type model) .................................................................................................................... 35 
Table 7:  Significant anatomical features contributing to the OAR DVH PCS2 (single-
disease type model) .................................................................................................................... 36 
Table 8: Significant anatomical features contributing to the OAR DVH PCS1 (multiple-
disease type model) .................................................................................................................... 37 
Table 9: Significant anatomical features contributing to the OAR DVH PCS2 (multiple-
disease type model) .................................................................................................................... 37 
Table 10: The mean value and S.D. of the bladder and their statistic test results .............. 41 
Table 11: The mean value and S.D. of the rectum and their statistic test results ............... 41 
 
 
  
ix
List of Figures 
 
Figure 1: Simulated phantom geometry and the dose distribution generated by the 
dynamic arc plan. (a) Transverse view.  (b) Sagittal view. (c) Dose distribution. The PTV 
is represented by the red sphere in the middle. The OARs are represented by the 
geometrical shapes on both sides of the sphere. Only some of the OAR volumes are 
shown here.. ................................................................................................................................... 8 
Figure 2: PTV-OAR anatomy of low-intermediate risk prostate cases.................................. 9 
Figure 3: PTV-OAR anatomy of high-risk prostate cases. ..................................................... 10 
Figure 4: PTV-OAR anatomy of anal rectal cases ................................................................... 15 
Figure 5: (a) Sagittal CT image showing the contours of PTV, bladder and rectum 
overlaid with isodose lines. (b) DVH for the bladder shown in the image. Bottom figures: 
Scatter plots of dose vs. distance to PTV surface for the voxels inside the bladder. (c) 
Euclidean distance is used for all voxels. (d) The variable distance model is used for 
voxels outside the treatment fields. Note the spread of dose-distance correlation is 
significantly reduced in (d). From Lulin Yuan et al., Quantitative analysis of the factors 
which affect the interpatient organ-at-risk dose sparing variation in IMRT plans, Med Phys, 
Volume(39), 6868-6878. ................................................................................................................ 18 
Figure 6: (a) Comparision between mean popularion DVH and individual patient’s 
DVH. (b) Comparison between the sum of the first two principle components and 
individual patients’s DVH deviation from mean population DVH. From Lulin Yuan et 
al., Quantitative analysis of the factors which affect the interpatient organ-at-risk dose sparing 
variation in IMRT plans, Med Phys, Volume(39), 6868-6878. .................................................... 20 
Figure 7: (a) Phantom OAR DTH. (b) Phantom OAR DVH. ................................................ 27 
Figure 8: (a): Correlation between PCS1 of DTH and the distance corresponding to 60% 
of OAR volume (d60). (b): Correlation between PCS2 of DTH and the average gradient 
of the DTH within a distance range (1.4 cm to 4.8 cm). ......................................................... 27 
Figure 9: (a): Correlation between PCS1 of DVH and the dose corresponding to 50% of 
Phantom OAR volume (D50). (b): Correlation between PCS2 of DVH and the average 
gradient of the DVH within a dose range (50% to 100%). ..................................................... 28 
  
x
Figure 10: Anatomical features of the bladder relative to primary PTV in different types 
of models. (a): Multiple-disease type combined. (b), (c), (d): Single-disease type ............. 30 
Figure 11: Anatomical features in femoral heads for boost PTV in different types of 
models. (a): Multiple-disease type model. (b), (c), (d): Single-disease type model ........... 32 
Figure 12: The S.D. of the prediction error for D50 and gEUD vs. the number of type 2 
cases added to train the model in different OARs. (a), (b): bladder, (c), (d): femoral 
heads, (e), (f): rectum. The red dashed line is the fitted line in the order of 
bxae c− + , and 
R squared of the fitting is shown in each figure. .................................................................... 33 
Figure 13: The S.D. of the prediction error for D50 and gEUD vs. the number of type 3 
cases added to train the model in different OARs. (a), (b): bladder, (c), (d): femoral 
heads. The red dashed line is the fitted line in the order of 
bxae c− + , and R squared of 
the fitting is shown in each figure. ........................................................................................... 34 
Figure 14: Correlation between actual DVH PCS1 (x-axis) and fitted DVH PCS1 (y-axis) 
for type 2 validation cases.......................................................................................................... 39 
Figure 15: Correlation between actual DVH PCS1 (x-axis) and fitted DVH PCS1 (y-axis) 
for type 3 validation cases.......................................................................................................... 40 
Figure 16: DVH for femoral heads in type 1 validation cases. ............................................. 43 
Figure 17: DVH for rectums in type 2 validation cases. ........................................................ 44 
Figure 18: DVH for bladders in type 3 validation cases. ....................................................... 45 
 
 
  
xi
Acknowledgements 
I would like to express my deep gratitude to Dr. Jackie Wu for her patient 
guidance, enthusiastic encouragement and valuable critiques as my advisor during my 
two-year study in the Medical Physics Graduate Program. I would also like to thank Dr. 
Oana Craciunescu and Dr. Timothy Turkington for serving as my committee members. 
Especially, I would like to thank Dr. Lulin Yuan who has been working on 
research that led to my thesis topic. My thesis work has benefited greatly from his 
experience and hands-on guidance.  
Lastly, I would like to thank my parents who have supported me both financially 
and morally.  
 
 
 
 
 
 
 
 
  
xii
List of Abbreviations  
BEV – Beam’s-Eye-View 
CTV – Clinical Target Volume 
D50 – The median dose (Dose received by 50% of the OAR volume) 
DTH – Distance-To-Target Histogram 
DVH – Dose Volume Histogram 
gEUD – Generalized Equivalent Uniform Dose 
GTV – Gross Tumor Volume 
GYN – Gynecology 
IMRT – Intensity Modulated Radiation Therapy 
MLC – Multi-Leaf Collimators 
MU – Monitor Unit 
MV – Mega-Voltage 
OAR – Organ-At-Risk 
OVH – Overlap Volume Histogram 
PCA – Principal Component Analysis 
PCS – Principal Component Scores 
PTV – Planning Target Volume 
S.D. – Standard Deviation 
VMAT – Volumetric Modulated Arc Therapy 
 1 
1. Introduction   
The primary goal of radiation therapy is to keep toxicity to normal tissues and 
critical organs at a minimum while maintaining the prescription dose coverage of the 
target. Compared to 3D conformal radiation therapy, intensity modulated radiation 
therapy (IMRT) and volumetric modulated arc therapy (VMAT) have the ability to 
provide improved dose sparing to organs-at-risk (OARs)1-3. With the help of multi-leaf 
collimators (MLC) and an optimization algorithm, optimal beam fluence pattern could 
be calculated4, 5 to achieve the optimization objectives (dose and volume limits to the 
OARs and the target) set by physicians and planners. In an ideal situation, the 
optimization objectives would reveal the best prescription dose coverage to the target 
with the lowest doses in OARs. In reality, physicians and planners can not know the 
“best dose sparing” for each individual patient in advance, so a trial-and-error method is 
commonly used during the treatment planning and optimization, and the process can be 
time consuming6. Also, the quality of IMRT/VMAT plans heavily depends on the 
planners’ experience7. Usually, a planner with more experience or expertise can achieve 
better dose sparing and/or fast planning time.  
In IMRT/VMAT treatment planning, planners often use optimization objectives 
from guidelines such as the RTOG clinical trials8 and published toxicity results like the 
QUANTEC9, 10. These OAR Dose Volume Histogram (DVH) guidelines are based on 
clinical toxicity endpoints; therefore, they represent the upper tolerable limits of the 
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OARs. Furthermore, these guidelines result from 3D conformal era and could be highly 
conservative for IMRT. The potential negative impact of using these optimization 
objectives is that many planning systems/algorithms will stop when the conservative 
objectives are met, albeit further sparing is achievable for an individual patient.  
Therefore, prescribing optimization objective doses that are as low as possible for each 
individual patient is important for IMRT/VMAT treatment planning. Previous studies 
have observed correlations of OAR dose sparing with the OAR Planning Target Volume 
(PTV) geometric relationships11-13. Using mathematical phantoms, Hunt et al. studied the 
dose distribution achieved in IMRT with varying PTV and OAR radii of curvature and 
different separation distances11. The authors found that the optimal dose distributions 
depend strongly on the PTV-OAR geometric relationship in the patient, in particular, the 
PTV-OAR separation distances, while the PTV and OAR radius of curvatures have little 
effect on the dose distribution when both are changed simultaneously. In another study 
of geometric factors influencing the dose sparing of parotid glands in head-and-neck 
cancer patients, Hunt et al. concluded that percent gland volume overlapping with PTV 
is the best predictor of mean gland dose12. While in prostate cancer cases, Reddy et al. 
reported that the mean dose to the rectum and bladder increases with increasing 
prostate volume and Clinical Target Volume (CTV)13. 
In general, the dose fall-off outside the PTV tends to correlate with the distance 
from the surface of the PTV11. In our earlier study, Zhu et al. used the Distance-To-
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Target Histogram (DTH) to describe the relative geometric relationships between the 
OAR and the PTV14. This method has been applied to evaluate the plan quality of 
automated IMRT plans of prostate cases. A similar geometric descriptor, the Overlap 
Volume Histogram (OVH), was proposed by Wu et al7. They implemented a head-and-
neck IMRT treatment planning method that uses OVH and related geometric features as 
criteria to select comparable plans from the database of prior patients to guide the 
planning of new patients15, 16. Similarly, Appenzoller et al. presented a knowledge-based 
planning model to reduce planning variability and improve treatment plan quality17. A 
set of training patients from a specific treatment site were identified and their minimum 
boundary distance between the OAR voxel and PTV were calculated. Then the OARs 
were divided into sub-volumes whose sub-DVHs were calculated and fitted with skew-
normal distribution. A three-parameter, skew-normal probability distribution was used 
to fit sub-volume dose distributions, and DVH prediction models were developed by 
fitting the evolution of the skew-normal parameters as a function of distance with 
polynomials.  
In a subsequent study, Yuan et al. built a mathematical model that described the 
relationships between the OAR sparing and an array of important anatomical features18, 
19. The models were trained by prior expert plans and were used to predict OAR sparing 
for prostate and head/neck cases. The modeling method has been implemented in the 
VarianTM treatment planning system. Users can generate a DVH prediction model for a 
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specific disease type using their own previous cases or adapt a model from other 
institutions. 
However, these knowledge models only work for a single type of cancer and 
they require a relatively large number of previous experts’ plans (>20) to train the 
model. In clinical practice, some disease types are located in the same region of a human 
body, and the OARs of these treatments share the same knowledge of toxicity 
guidelines. Hence, a knowledge model that provides OAR sparing guidance for multiple 
disease types offers integration of clinical resources and expertise. 
Further, these single disease type knowledge models are trained in a batch 
mode14, 18. In this mode, the user collects a number of prior clinical plans to be included 
in a training dataset. Considerable resources are needed in order to construct a training 
dataset, in addition to the time spent on planning a case. The user needs to identify 
plans from a clinical database, matching structure names, and to extract or export the 
plans. The user also must set aside an adequate number of cases for model validation. 
The number of training cases is determined based on the user’s experience or a trial-and-
error process. This modeling is repeated for each disease type. Such a training pathway 
is not very efficient as the user has little interaction with the training process and no 
control over the final accuracy and resources spent on the learning process.  
The current study tries to expand the existing knowledge modeling in two areas. First, 
we investigate the feasibility of using one knowledge model to predict the dose sparing 
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in the common OARs for multiple disease types. Second, we investigate an efficient way 
to train such model. Progressive modeling is a more efficient pathway for DVH model 
training20. During progressive modeling, the cases from a different disease type with 
different PTV but similar OARs are gradually added to the training pool one by one, and 
an intermediate model is constructed at each step. A carefully designed validation 
process is carried out for each intermediate model to estimate the current accuracy. This 
information continuously refreshes whenever a new intermediate model is produced. 
The user can easily experiment with different algorithms, parameters, and feature 
selections at each step. The user may stop the learning process when the model accuracy 
stops improving20. The progressive modeling method is an especially suitable method to 
train a multiple disease model because it takes advantage of the prior knowledge about 
the dose sparing for the similar OARs from another disease type by adding cases from 
another disease type to the training datasets.  
The work of this thesis is constructed as follows. First, we validated the 
knowledge modeling process with a mathematical phantom of the pelvic area. A series 
of geometric volumes representing the PTV and OARs were simulated in the pelvic 
phantom.  The geometry and dose-volume distribution in these structures were studied 
in order to establish a fundamental understanding of the geometrical factors that 
influence the dose distribution in the OARs. Then a progressive study was conducted to 
investigate the feasibility of expanding the single-disease type model to predicting OAR 
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sparing for multiple disease types in the pelvic region, using de-identified cancer patient 
cases. And finally, the performance of the multiple-disease type model was evaluated 
against single-disease type models for its potential clinical usefulness.
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2. Methods and Materials 
2.1 Mathematical phantoms 
The PTV in the phantom study was constructed with a sphere of 5 cm radius 
while a group of OARs were constructed with volume and shape variations and were 
placed at varying distances from the PTV. There were three basic shapes: box, half-
sphere and the concave portion of a sphere (which is the volume formed between two 
eccentric spherical surfaces). The boxes also had different length-to-width ratios. The 
distances from the center of the OARs to the PTV surface ranged from 2 cm from inside 
(overlap) to 7 cm from outside. The shape and relative position of the OARs to the PTV 
are shown in Figure 1.  
The dose distribution for this phantom PTV was generated by a dynamic arc 
plan with the goal of providing uniform dose coverage to the PTV. The 360 degree 
rotation of the beam in the dynamic arc eliminated any beam angle influence or 
preference to any of the OARs. The beam aperture/segment was defined by the 
projections of the PTV in the Beam’s-Eye-View (BEV) at each gantry angle. Since the arc 
plan offered no explicit sparing to any of the OARs (i.e., no optimization objectives were 
used), the resulting DVHs of these OARs were due entirely to their shape and geometry 
relative to the target. Moreover, there was no interference or competition among OARs 
for sparing, so all OARs could be pooled together as one single OAR group.  
 Figure 1: Simulated phantom geometry and the dose distribution generated by the 
dynamic arc plan. (a) Transverse view.  (b) Sagittal view. (c) Dose distribution. The 
PTV is represented by the red sphere in the middle. The OARs are represented by the 
geometrical shapes on both sides of the sphere. Only some of the OAR volumes are 
shown here. 
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2.2.1.3 OAR constraints for prostate cancer IMRT/VMAT planning  
Table 1 shows different types of PTVs and the corresponding dose prescriptions 
for prostate IMRT/VMAT. The physician’s prescription of dose constraints for the OARs 
followed an institutional template as shown in Table 2. These OAR constraints are 
population-based and do not take into account the variations of individual patients’ 
anatomy and physiological conditions (full vs. empty bladder, etc.). The planner starts 
optimization with these template-based OAR objectives and uses a trial-and-error 
method to search the optimal OAR sparing for a given patient’s anatomy. This iterative 
process continues until the planner is satisfied with the OAR sparing for that patient. 
The planner then presents the plan for physicist/physician review. If the reviewers feel 
further OAR sparing can be achieved, the trial-and-error process is continued until the 
physician approves the plan. 
 
Table 1: Dose prescriptions and PTVs in different types of prostate cancer 
Prescription  
Target Margin Prescription 
Postop PTV (Prostate Bed) Zero 66 Gy/33 Fractions 
Intact Low-Risk PTV (Prostate + Margin) Zero  76 Gy/38 Fractions 
Intact 
Intermediate-Risk 
PTV1 (Prostate + SV) Zero 54 Gy/27 Fractions 
PTV2 (Prostate) Zero 22 Gy/11 Fractions 
Intact High-Risk  PTV1 (Prostate +SV+ LN) Zero 45 Gy/25 Fractions 
 12 
PTV2 (Prostate + SV) Zero 10 Gy/5 Fractions 
PTV3 (Prostate) Zero 22 Gy/11 Fractions 
 
 
Table 2: Normal tissue constraints for prostate IMRT used in Duke University Cancer 
Center 
 
 
 
Constraints  Postop Prostate  Intact Prostate  
OARs Dose (Gy) Volume (Absolute or %) Dose (Gy) Volume (Absolute or %) 
Bladder 70 <10 cc 75 <10 cc 
Bladder 65 50% 65 25% 
Bladder 40 70% 40 40% 
Rectum 70 <10 cc 75 <10 cc 
Rectum 65 35% 65 17% 
Rectum 40 55% 40 40% 
Lt Femoral 
head 
50 0% 50 0% 
Rt Femoral 
head 
50 0% 50 0% 
Penile bulb 30 15% 30 15% 
Small bowel 45 1% 45 1% 
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2.2.2 Anal rectal cancer IMRT plans (type 3) 
For the 36 anal rectal IMRT plans, the dose prescriptions for the PTV volumes 
varied according to the disease stage21. One primary PTV with one or two boost PTVs 
was common in anal rectal plans. Nine to eleven 15 MV beams were used to design the 
IMRT plan. Anal rectal plans are assigned as type 3 plans in this study. The OARs of 
type 3 cases share some of the common OARs with type 1 and type 2 such as the bladder 
and the femoral heads. The rectum in this type is no longer an OAR. 
In anal rectal IMRT planning, there was no institutional template for dose 
constraints. Instead, physicians carefully examined patients’ anatomy and clinical 
indications and prescribed the dose constraints on a case-by-case basis. Constraint for 
bladder volume and dose ranged from 40% to 70% and 10 Gy to 30 Gy, respectively. For 
femoral heads, the prescription for the maximum dose limit ranged from 40 Gy to 50 Gy. 
In some cases, 50% volume of femoral heads received lower than 20 Gy to 35 Gy of dose. 
Table 3 and Table 4 are example prescriptions of a customized anal rectal cancer case. 
Figure 4 shows the PTV-OAR anatomy of anal rectal cancer plans.  
Table 3: Dose prescriptions and PTVs in an example of the customized anal rectal case 
Prescription  
Target Margin Prescription 
PTV 3600 Final None 1.8/36 Gy 
PTV 4500 Final None 1.8/45 Gy 
PTV 5400 Final None 1.8/54 Gy 
 Table 4: Normal tissue constraints for a
 
Figure 4: PTV-OAR anatomy of anal rectal cases
2.3 Knowledge-based 
The knowledge-based OAR sparing modeling method 
established by Zhu et al. 
Constraints 
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14 
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research is based on this modeling method, the fundamental elements of this method are 
described in this section.  
2.3.1 Anatomical and dosimetrical features for knowledge modeling 
Volume is one major anatomical feature that can influence the OAR DVH13 14. 
Thus, the general volume parameters such as the OAR and PTV volumes, and the 
special fractional volume parameters such as the fraction of OAR volume overlapping 
with PTV (referred to as “overlap volume” in this study) and the fraction of OAR 
volume outside the radiation treatment fields (referred as “out-of-field volume” in this 
study) were chosen to represent patient anatomical features. Aside from the volume, the 
geometry of the OAR and its relative position to the PTV also affect the dose deposited 
in the OAR. Therefore, the DTH was included in the analysis to represent the relative 
geometrical relationships between the OAR and the PTV14. The value of DTH at a 
distance bin d (V(d)) is the fraction of OAR volume with its maximum distance to the 
PTV surface less than d: 
 
   
	
|  	
   and 	
 , PTV  
	
| 	
   
, 
 
where is some metric that measures the distance between voxel  in the OAR and the 
PTV. The simplest form of is14:  
	
 , PTV  min

  |  	   !". 
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Negative signs are assigned to the distance values for OAR voxels inside PTV to indicate 
the intrusion of OAR into the PTV.  
For pelvic IMRT where beams are configured coplanar, there are cases where 
large portion of the OAR volumes are outside the treatment fields. An example is shown 
in Figure 5(a). In this case, the bladder is positioned largely superior to the PTV. The 
voxels outside the primary beam entrance (superior to the beam edge) receive only 
scatter dose and have different dose-distance correlations from the other voxels. To 
account for this beam configuration effect, a variable distance metric for these out-of-
field voxels was applied. We used a modified distance metric for such voxel, which 
includes an additional factor which is its distance to the PTV along z-direction (the 
superior-inferior direction)14: 
$	
, PTV  	
, PTV % min
&
|'
  '||'  is the z‐coordinate of voxel k inside PTV, 
where is the z-coordinate of the voxel . This modification increases the distance of this 
voxel to the PTV so that dose-distance correlation spread is greatly reduced (Figure 
5(d)). Table 5 lists the OARs and their anatomical features analyzed for this study. 
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Table 5: The OARs and their anatomical features analyzed in this study 
Site OAR Anatomy feature 
Low-intermediate 
risk prostate cases 
Bladder Distance-To-Target Histogram (DTH) 
High-risk prostate 
cases 
Rectum OAR volumes 
 Femoral heads PTV volume 
Anal rectal cases Bladder Fraction of OAR volume overlapping 
with PTV (overlap volume) 
 Femoral heads Fraction OAR volume outside the 
treatment fields (out-of-field volume) 
  PTV dose coverage and dose 
homogeneity 
  Tightness of geometrical enclosure of 
PTV surrounding OAR (PTV 
surroundings) 
 
 
 Figure 5: (a) Sagittal CT image showing the contours of PTV, bladder and rectum 
overlaid with isodose lines. (b) DVH for the bladder shown in the image. Bottom 
figures: Scatter plots of dose vs. distance to PTV surface for the voxels inside the 
bladder. (c) Euclidean distance is used for all voxels. (d) The variable distance model 
is used for voxels outside 
correlation is significantly reduced in (d).
analysis of the factors which affect the interpatient organ
variation in IMRT plans, 
 
2.3.2 Principal component 
The DTH is a continuous function of distance. Discretization of this function 
results in high dimensional data. However, the shapes of the DTH curves have similar 
features, which suggest the discrete bins are highly correlated.  The same observation 
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also applies to the DVH. Therefore, Principal Component Analysis (PCA) was applied to 
DVHs and DTHs to reduce their dimensions and select the most significant features14, 23. 
Each DTH and DVH was treated as multiple dimensional vectors. Each component of 
the vectors corresponds to one histogram bin. The principal components are calculated 
from the covariant matrix of the DTH or DVH curves among the training samples, and 
they represent the dominant modes of the variability of the histograms. The individual 
histograms can be expressed as the linear combinations of these dominant modes, and 
the coefficients of the linear expansions are the Principle Component Scores (PCS). These 
dominant modes are ranked by the eigenvalues of the covariant matrix. The DTH and 
DVH histograms can be represented in the principle component space by their principle 
component scores.  
As shown in Figure 6 (a), the solid line represents a DVH for an individual 
patient, and the dashed line represents the mean DVH of all DVHs for this organ in the 
training pool. The differences between the individual patient’s DVH and mean 
population DVH is shown by the blue solid line in (b). The red dashed line and green 
dashed line in (b) are the first and second principle components, respectively. The blue 
dashed line is the sum of the first two principle components. From this figure we can see 
that the individual patient’s DVH is almost the same as the sum of the first two principle 
components. Much of the variability of the histograms can be accounted for by a small 
 number of principle components. In this study, the first three componen
were selected as anatomical features.
 
Figure 6: (a) Comparision between mean popularion DVH and indi
DVH. (b) Comparison between the sum of 
individual patients’s DVH deviation from mean 
et al., Quantitative analysis of the factors which affect the interpatient organ
dose sparing variation in IMRT plans
 
2.3.3 Correlation between patient anatomical features and 
sparing features 
We seek to identify the correlation between patient anatomical features and the 
corresponding OAR dose sp
method was utilized to find the correlation between patient anatomical features and the 
corresponding DVHs14. S
stepwise regression method adds 
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eliminates the least significant one at each step of regression so that only the significant 
factors are included in the final model. To indicate the significance of each individual 
factor, we used the coefficient of partial determination, which measures the residual 
correlation between that factor and the residual part of the DVH variation not explained 
by the factors already included in the model24. The models were constructed separately 
for each OAR and both linear and the higher order terms of the DTH PCS were included 
in the regression analysis to account for the nonlinear effect. 
 
2.4 Building a knowledge model for multiple disease type  
This study contains two aims. The first aim is to build a knowledge model for 
multiple disease type cases in the pelvic region.  Second, we introduce a progressive 
modeling method in order to train the model more efficiently. 
2.4.1 Variation of anatomical features of each type cases 
For all three types of cases, the first three principle component scores (PCS1, 
PCS2 and PCS3) and anatomical features were calculated for each OAR in every case. 
The median and interquartile range of them were calculated and presented in boxplots. 
To generate a model for all three disease types, the variance of the OAR features in 
training cases should cover the ranges of all cases. 
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2.4.2 The process of progressive modeling 
The knowledge model has demonstrated high efficacy on OAR sparing 
prediction for low-risk prostate IMRT planning, according to the previous results19. 
Therefore we started the progressive modeling process with 20 low-intermediate risk 
prostate (type 1) plans. Cases with more complex PTV-OAR anatomies (prostate with 
lymph node irradiation, type 2 and anal rectal, type 3, respectively) were added to the 
training dataset one by one until the model prediction accuracies reached plateau.  An 
intermediate model was saved at each step. The correlation between the model 
prediction accuracy and the number of training cases from type2 (or 3) were recorded. 
The number of cases to train a DVH prediction model for all three disease types 
(multiple-type model) with stable accuracy was determined.   
In order to reduce both the effect of outliers and the variability of the validation results, 
we randomly separated the cases in type 2 and type 3 datasets into two groups with the 
same number of cases in each group. For each iteration, a given number of cases from 
one group was chosen to train the intermediate model, and all cases in the other group 
were used to test the model.  This step was repeated three times, and each time a 
different set of training cases was randomly selected from that group. Then we switched 
the training group and testing group and repeated the process.  This process was done 
for type 2 and type 3 cases separately. In total, six validation data sets were generated 
for each given number of training cases from type 2 or type 3 datasets. 
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For validation tests, dosimetric parameters were extracted from the predicted 
DVHs and actual DVHs for each OAR. The mean value and the standard deviation 
(S.D.) of the differences between predicted values and actual plan values provided the 
accuracy evaluation of the intermediate models. We expect the mean and S.D. of the 
prediction accuracy to decrease initially when more type 2 (or type 3) cases are added to 
the training.  The mean and S.D. become stable and the prediction accuracy of the model 
reaches a plateau when the cases added to the training can represent the whole range of 
the different anatomical and dosimetric features of the patient cases.  We consider 
prediction accuracy becoming stable when the changes of the mean and S.D. are less 
than 1% of the prescription dose. At this point, the minimum number of type 2 (or type 
3) cases required for a multiple-disease type model is reached. 
2.4.3 Dosimetric parameters for evaluating the models 
In this study, D50 and gEUD values were extracted from the predicted DVHs to 
evaluate the models. D50 represents the median dose (dose received by 50% of the OAR 
volume). Median dose is an important dose index in both dose prescription and RTOG 
guidelines for cancers in the pelvic region21, 25. The generalized equivalent uniform dose 
(gEUD) is a phenomenological model to reduce the dose distribution of a structure into 
a single biologically relevant index26:  
11( )i
i
gEUD D
N
α α= ∑
,
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where N is the number of voxels in the anatomic structure of interest, Di is the dose in 
the ith voxel, and α is the tumor or normal tissue-specific parameter that describes the 
dose-volume effect. The α value is chosen as six for both bladder and rectum and four 
for femoral heads27.  
2.5 Accuracy evaluation of multi-disease type model 
The minimum case numbers found in the progressive study for type 2 and type 3 
plans were used to train the multiple-disease type model (along with 20 type 1 plans). 
To evaluate the prediction accuracy, the DVHs predicted by the knowledge model for 
the bladder, the femoral heads and the rectum were validated with 20, 9 and 18 cases 
from type 1, 2, and 3 geometries, respectively (rectum DVHs were omitted for type 3). 
The differences between the predicted D50 and gEUD values and the actual plan values 
of each OAR were extracted from corresponding DVH curves and their mean value and 
S.D. were calculated.  
The prediction accuracy of models trained by single-disease type cases was 
defined as reference for the multi-disease type model. Half of the cases in our dataset— 
20 from type 1, 9 from type 2, and 18 from type 3—were used to train three single-
disease type models, respectively. The same cases used to validate the multiple-disease 
type model were also used to validate the accuracy for single-disease type models.  
The statistical significance of the difference between the means of prediction 
error by the multiple-disease type model and the single-disease type models was tested 
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by t-test, and that of the differences between the S.D. was tested by an F-test. The two-
sample F-test was used to test if the variances of two populations were equal,  
 
where s1 and s2 are the sample S.D. If the p-value of both tests are greater than 0.05, it 
means no significant differences between the results of two models. 
In addition, another F-test was utilized to determine if one of the single-disease 
type or multiple-disease type models better fit the training data than the other one28. 
This test was based on the training cases only and did not depend on the selection of 
validation cases. The residual sum of squares (SS1 and SS2) of the predicted PCS1 and 
degree of freedom (df1 and df2) for the two models were calculated to derive the F 
value:  
( 1 2) / ( 1 2)
2 / 2
SS SS df dfF
SS df
− −
=  
For each model, there were N – V degrees of freedom. In this study, N was the 
number of training cases of each model and V was the number of selected features. The 
first model must be the one with fewer parameters (i.e., the simpler one). The F-statistic 
and degrees of freedom can be used to determine the p-value. A p-value less than α
(=0.05) indicates that the more complex model (denominator of F-statistic) fits the data 
significantly better than the simpler model. 
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3. Results 
3.1 The analysis of the results from mathematical phantom 
The modeling method was applied to a mathematical phantom. Figure 7 shows 
the DTH and DVH curves for a number of phantom simulations. A total of nine OARs 
with different shapes were tested in the phantom. The PCA shows that two components 
of PCS can explain more than 95% of the variation of the DVH of all OARs, and at most 
three components of DTH PCS are needed to represent the DTH variation at the same 
level. Each of the first two principal components of the coefficient vector measures the 
importance of the corresponding data point or histogram bin to the principal 
component29. The first principal component represents a unidirectional contribution by 
all data points with one extreme value (Figure 6). It suggests that the first principal 
component can be associated with a single volume value or its corresponding dose or 
distance value. On the other hand, the second principal component has two extreme 
values with opposite signs. This suggests the second principal component can be 
interpreted as the interaction of fractional volumes at two different dose or distance bins, 
or in other words, it is associated with the fractional volume within these two extreme 
distance or dose values. 
 Figure 7: (a) Phantom OAR DTH. (b) Phantom OAR DVH.
The first principal component score (PCS1) of the DTH is found to be strongly 
correlated with the distance corresponding to 60% OAR volume (d60): the correlation 
coefficient R is at or above 0.98 for 
median distance (d50) between the PTV and the OAR with the correlation co
being 0.99 for the phantom OARs (
Figure 8: (a): Correlation between PCS1 of DTH and the distance corresponding to 60% 
of OAR volume (d60). (b):
gradient of the DTH within a distance range (1.4 cm to 4.8 cm).
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phantom OARs. It is also closely related to the 
Figure 8). 
 Correlation between PCS2 of DTH and the average 
 
 
efficient R 
 
 Similar to the DTH, the first DVH PCS (PCS1) and the D50 (the dose 
corresponding to 50% OAR volume) have strong correlation: the cor
is in the range of 0.98 for 
the OAR. This result is consistent with the observation reported by M.Sohn e
Zhu14. 
Figure 9: (a): Correlation between PCS1 of 
Phantom OAR volume (D50).
gradient of the DVH within a dose range
The PCS2 of DVH 
within a dose range. For the real treatment cases, the range is between 10% and 50% of 
the dose. For the phantom, the range is between 50% and 100% of the dose. The largest 
variations of DVH gradient occur within these 
In summary, the phantom study helped to understand how the radiation physics
characteristics influence the OAR sparing
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relation coefficient R 
the phantom OAR (Figure 9). It represents the median dose in 
DVH and the dose corresponding to 50% of 
 (b): Correlation between PCS2 of DVH and the average 
 (50% to 100%).      
correlates strongly with the average gradient of the DVH 
ranges.   
. Based on these understanding
t al. 23 and X. 
 
’ 
s, a series of 
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anatomical features have been selected empirically to formulate the correlation with 
dosimetric features in the IMRT/VMAT plan. 
3.2 Progressive modeling 
3.2.1 Variations of different anatomical features scores  
To show the distributions of the anatomical features of different disease types, 
the variations in anatomical features of each OAR were drawn as boxplots. The first 
principle component of DTH (DTH PCS1), overlap volume, out-of-field volume, volume 
of OAR, volume of PTV and tightness of the geometrical enclosure of PTV surrounding 
OARs were shown. 
 
 Figure 10: Anatomical features 
types of models. (a): Multiple
In Figure 10, the distribution of the 
primary PTVs are shown in boxplots. Some variations of anatomical features in different 
disease types could be different because of the geometr
instance, the distributions of PTV volume change greatly from type to type
volumes of primary PTV in low
not vary significantly from case to case. However, in high
(c)) cases and anal rectal cancer (type 3, (d)) cases, the volumes of primary PTV depend 
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of the bladder relative to primary PTV in different 
-disease type combined. (b), (c), (d): Single
anatomical features of the bladder relative to 
ic relationship differences. For 
-intermediate risk prostate cancer (type 1, (b)) cases do 
-risk prostate cancer (type 2, 
 
-disease type.  
. The 
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on the patient’s anatomical geometry and the stage of the cancer. The volumes can vary 
significantly from case to case as a result.   
The same trend can be found in the distribution of femoral head features relative 
to boost PTVs, as shown in Figure 11. The boost PTVs of prostate cancer (type 1 (b) and 
type 2 (c)) cases do not extend laterally to the femoral heads, so the ranges of PTV 
surrounding features are small. However, in anal rectal (type 3 (d)) cases, due to the 
larger volume of boost PTVs, femoral heads can be surrounded by the boost PTVs in 
some cases, so the variation in this anatomical feature is greater. 
 Figure 11: Anatomical features in 
models. (a): Multiple-disease type model. (b), (c), (d): Si
 
3.2.2 Results for prostate with lymph nodes cases
Figure 12 shows the trend of 
added to the modeling process.  For bladder
to achieve stable prediction accuracy, as shown in Figure 
Figure 12 (c) and Figure 12
as the minimum number of type 2 cases needed for a pr
32 
femoral heads for boost PTV in different type
ngle-disease type model
 (type 2)
S.D. reduction when additional type 2 cases are 
 gEUD, adding five type 2 cases are enough 
12 (b). In some cases, like 
 (f), seven cases are required to reach a plateau. We choose 
ogressive model.
 
s of 
 
  
six 
 
  
Figure 12: The S.D. of the prediction error for
cases added to train the model
heads, (e), (f): rectum. The red dashed line is the fitted line
and R squared of the fitting is shown in each figure.
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 D50 and gEUD vs. the number of type 2 
 in different OARs. (a), (b): bladder, (c), (d): 
 in the order of 
 
 
femoral 
bxae c− + , 
 3.2.3 Results for anal rectal
The same analysis was performed for type 3 cases. From Figure 
trend of S.D. reduction is observed. In Figure 
plateau for D50 when six
cases to achieve stable predictions (Figure 
minimum number for type 3 cases.
Figure 13: The S.D. of the prediction error for
cases added to train the model
heads. The red dashed line is the fitted line in the order of 
the fitting is shown in each figure.
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13 (a) and (c), the prediction errors reach a 
 type 3 cases are added. For gEUD, it takes eight
13 (b) and (d)). Thus we choose 
 
 D50 and gEUD vs. the number of type 
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3.3 Evaluation of the knowledge models in pelvic region 
As shown in the previous section, the minimum numbers of type 2 and type 3 
cases needed to reach stable prediction accuracy are six and eight, respectively. 
Therefore, the multiple-disease type model was trained with twenty type 1 cases, six 
type 2 cases and eight type 3 cases. To evaluate the performance of this multiple-disease 
type model, several model properties and model prediction outcomes are compared 
with those of single-disease type models. 
3.3.1 Significant anatomical features of the models 
To understand the similarities and differences between the single-disease models 
and the multiple-disease models, significant factors contributing to OARs sparing were 
extracted by the stepwise multiple regression method. The significant factors are 
identified with p-value < 0.05. The partial determination coefficient for each factor 
individually and the multiple determination coefficients by all of these factors combined 
are listed in Tables 6 - 9. Bladders and rectums are two major OARs in prostate cancer 
cases, so the DVH PCS1 and DVH PCS2 for bladder in type 3 cases and for rectum in 
type 2 cases are listed.  
Table 6: Significant anatomical features contributing to the OAR DVH PCS1    
(single-disease type model) 
Bladder DVH PCS1 (in type 3) Rectum DVH PCS1 (in type 2) 
Significant Factors R2 Significant Factors R2 
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 Overlap Volume  
(Primary PTV) 
0.22 Second order of  DTH PCS 1 
 (Primary PTV) 
0.55 
Dose homogeneity  
(Primary PTV) 
0.21 PTV Surrounding Volume  
(Primary PTV) 
0.51 
  Second order of  DTH PCS 1 
(Boost PTV) 
0.23 
Combined 0.39  0.95 
 
Table 7:  Significant anatomical features contributing to the OAR DVH PCS2   
(single-disease type model) 
Bladder DVH PCS2 (in type 3) Rectum DVH PCS2 (in type 2) 
Significant Factors R2 Significant Factors R2 
Overlap Volume  
(Primary PTV) 
0.26 DTH PCS 2  
(Primary PTV) 
0.83 
PTV d95  
(Primary PTV) 
0.25   
Combined 0.48  0.83 
 
 
 37 
Table 8: Significant anatomical features contributing to the OAR DVH PCS1 
(multiple-disease type model) 
Bladder DVH PCS1  Rectum DVH PCS1  
Significant Factors R2 Significant Factors R2 
 DTH PCS1  
(Primary PTV) 
0.79 DTH PCS1  
 
(Primary PTV) 
 
0.48 
PTV Surrounding Volume 
(Primary PTV) 
0.16 Out- Of-Field Volume  
(Primary PTV) 
0.42 
  OAR Volume  
(Primary PTV) 
0.10 
Combined 0.89  0.76 
 
Table 9: Significant anatomical features contributing to the OAR DVH PCS2 
(multiple-disease type model) 
Bladder DVH PCS2  Rectum DVH PCS2  
Significant Factors R2 Significant Factors R2 
 DTH PCS3 
(Primary PTV) 
0.29 DTH PCS3  
(Primary PTV) 
0.59 
Out-Of-Field Volume  
(Primary PTV) 
0.19 PTV Volume  
(Primary PTV) 
0.13 
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  Overlap Volume  
(Primary PTV) 
0.16 
  DTH PCS2  
(Primary PTV) 
0.20 
Combined 0.44  0.81 
 
As we can see, the PCS of the DTH, the overlap volume, the out-of-field volume, 
the tightness of the enclosure of PTV surrounding OAR and the dose homogeneity of the 
PTV all contribute to OAR dose sparing. For DVH PCS1 of the bladder in the single-
disease type model, the most significant factor is overlap volume, while in the multiple-
disease type model, the most significant factor is DTH PCS1.  And the combined 
determination coefficients for bladder DVH PCS1 in the multiple-disease type model is 
significantly greater than that in the single-disease type model (0.89 vs. 0.39). The most 
significant factor for DVH PCS1 of the bladder in both the single- and multiple-disease 
type models is DTH PCS1. 
3.3.2 Correlation of actual DVH PCS and fitted DVH PCS 
In 3.3.1 and 3.3.2, the properties of the single-disease type model and the 
multiple-disease type model are compared. In this section, validation cases from each 
disease type are tested to compare the prediction outcomes of the models. The 
 correlations between actual DVH 
validation cases are shown
Figure 14: Correlation between actual DVH PCS1
axis) for type 2 validation cases.
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PCS1 and fitted DVH PCS1 of the type 2 and type 3 
 in Figure 14 and Figure 15, respectively. 
 (x-axis) and fitted DVH 
 
 
PCS1 (y-
 Figure 15: Correlation between actual DVH PCS1 
axis) for type 3 validation cases.
We can see the correlation between the fitted and the actual DVH PCS1 for both 
the single- and multiple-disease type cases. And the 
disease type cases are generally higher than in single
3.3.3 Statistic tests
The prediction accuracy 
models were compared for each OAR
the means of their prediction errors were tested by
differences of the S.D. of their prediction error
values and S.D. of the model 
results were listed in Table 
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(x-axis) and fitted DVH PCS1 
  
correlation coefficients in multiple
-disease type cases.
 of the single/multiple-disease type
of the multiple-disease type and single-disease 
. The statistical significance of the differences of 
 the student’s t-test, and the 
s were tested by the F-test. The mean 
prediction errors and their corresponding statistic test 
10 and Table 11.  
 
(y-
-
 
 models 
type 
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From these two tables, it can be observed that these is no significant difference 
between single-disease type and multiple-disease type models; the p-values for both 
tests are higher than 0.05.   
Table 10: The mean value and S.D of the bladder and their statistic test results 
OAR Bladder 
Geometric 
type Prostate (type1) Prostate w LN (type2) Anal rectal (type3) 
Dose 
Parameters D50 gEUD D50 gEUD D50 gEUD 
Single type -5.00±6.07 -2.6±12 -2.80±11.61 -1.0±8.7 -1.84±13.35 -2.2±5.2 
Multi-type -4.77±4.76 -0.28±9.6 -5.96±11.59 -1.8±8.4 4.85±9.53 0.30±7.7 
t-test 
 (p-value) 0.89 0.51 0.57 0.77 0.09 0.27 
F-test 
 (p-value) 0.30 0.38 1.00 0.87 0.17 0.09 
 
 
Table 11: The mean value and S.D. of the rectum and their statistic test results 
OAR Rectum 
Geometric 
type Prostate (type1) Prostate w LN (type2) 
Dose 
Parameters D50 gEUD D50 gEUD 
Single type -1.05±9.67 -2.2±5.1 -5.00±7.26 -0.83±3.3 
Multi-type -2.35±7.96 -1.7±4.1 -1.93±5.6 -0.73±3.0 
t-test 
(p-value) 0.65 0.76 0.33 0.92 
F-test 
(p-value) 0.41 0.35 0.49 0.64 
 
The capability of the multiple-disease type and single-disease type models to fit 
the training data was compared by another F-test. The p-values for comparing the 
multiple-disease type rectum model and the single-disease type rectum model trained 
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by type 2 cases only is 0.33, and it is 0.49 for the bladder model. Comparing with single-
disease type bladder model trained by type 3 cases only, the p-value is 0.57. Therefore, 
for these two OARs, no significant differences exist between single-disease type models 
and multiple-disease type models. 
3.3.4 DVHs of validation cases 
DVHs of validation cases were plotted and are shown in Figures 16 - 18. Blue 
lines are actual OAR DVH extracted from clinical IMRT plans, and the red lines are 
model-predicted OAR DVH. One typical OAR was chosen for each disease type. As we 
can see, the predicted DVH curves are generally consistent with the actual plan DVHs. 
 Figure 16: DVH for femoral heads in type 1 validation cases.
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 Figure 17:  DVH for rectums in type 2 validation cases.
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 Figure 18: DVH for bladder in type 3 validation cases.
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4. Discussion 
The treatment plan in the phantom study was created with a single objective to 
cover the PTV without considering OAR sparing. Therefore, the DVH-DTH correlation 
in the phantom study represents purely the effect of individual OAR shape and 
geometry relative to the target. The results confirm that the only significant factor for the 
PCS1 of OAR DVH is the DTH PCS1, with a determination coefficient R2=0.99. Since the 
DTH PCS1 highly correlates with the median distance of OAR to PTV and the DVH 
PCS1 highly correlates with the median dose, we can interpret the correlation of DTH-
DVH PCS in terms of the physical parameters: the correlation indicates the influence of 
median distance on median dose. For DVH PCS2 of the phantom OAR, DTH PCS2 is the 
only significant factor with R2=0.86. This correlation can similarly be interpreted to 
indicate that the DTH gradient influences the gradient of DVH.  
In summary, the PTV-OAR geometry can be represented by the PCS1 and PCS2 
of the DTH, and they are capable of explaining the dominant part of OAR dose variation 
in phantom plans. Other anatomical features, mostly volume based, have minimal 
contribution, indicating the DTH is capable of representing most of the anatomical 
contributions on DVH for the phantom case. 
Geometric differences in the pelvic region cause the various ranges of the 
distributions of each anatomical feature in each disease type. As a result, a model 
trained with one disease type anatomy could not provide an accurate DVH sparing 
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prediction of cases from other disease types. So, cases from all three disease types were 
pulled together to train a multi-disease model. As shown in Figure 10 (a) and Figure 11 
(a), the ranges of distributions of each anatomical feature could cover the ranges in each 
single-disease type anatomy, and the model has the ability to predict DVH sparing for 
different disease types.  
The significant factors contributing to OAR dose sparing in the multiple-disease 
type model and in the single-disease type models are extracted for comparison. As the 
results in Tables 6 - 9 show, the combined determination coefficient of DVH PCS1 in the 
bladder from type 3 cases is 0.39 when trained with type 3 cases alone and has increased 
to 0.89 when trained with all three disease type cases. This may be because the increased 
number of training cases has reduced the statistical fluctuation.  
The F-test of the statistical significance of the difference between the S.D. of 
prediction error by the multiple-disease type model and the single-disease type models, 
the t-test for the difference of the mean-value of prediction errors and F-test to compare 
the capability of the two models to fit the training data indicate no significant differences 
in quality and consistency between the single-disease type models and the multi-disease 
type models. Thus, a multi-disease model can be built to provide the DVH sparing 
prediction of all three disease type cases.  
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5. Conclusion 
The progressive modeling allows fast model training with minimum data 
involved and represents the capability of self-evolution when additional data or features 
are added. In this study, we did a feasibility study for diseases in the pelvic region. 
Using this method, we could generate an OAR sparing guidance model for multiple 
disease types in the same body region more efficiently. Previous resources and 
knowledge could be better utilized when applying the progressive model. Progressive 
knowledge modeling of OAR sparing for multiple cancer types in the pelvic region is 
feasible and has comparable accuracy to single-disease type modeling. 
The gynecology (GYN) cases are also in the pelvic region as are three types of 
cancers in this study. The philosophy of this progressive modeling could be utilized in 
GYN cases to build a universal model for cases in the pelvic region.  
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